Achmea Investment Management B.V. Buys 710 Shares of Solventum Co. (NYSE:SOLV)

Achmea Investment Management B.V. increased its stake in Solventum Co. (NYSE:SOLV) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,332 shares of the company’s stock after acquiring an additional 710 shares during the period. Achmea Investment Management B.V.’s holdings in Solventum were worth $1,079,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of SOLV. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum during the 3rd quarter valued at about $125,488,000. Trian Fund Management L.P. increased its holdings in Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. purchased a new position in Solventum during the 3rd quarter valued at about $50,948,000. Nordea Investment Management AB increased its holdings in Solventum by 189.5% during the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after purchasing an additional 431,986 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Solventum during the 4th quarter valued at about $18,583,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SOLV. Wells Fargo & Company upped their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. The Goldman Sachs Group upped their target price on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. Finally, Piper Sandler upped their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $79.86.

Solventum Stock Performance

Solventum stock opened at $74.31 on Friday. The company has a market capitalization of $12.85 billion and a P/E ratio of 27.02. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock’s 50 day moving average is $74.52 and its 200 day moving average is $71.14.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.